12:00 AM
Apr 11, 2011
 |  BioCentury  |  Product Development

Ligand approach to IGF

MedImmune MEDI-573 targets ligands in IGF pathway, where many cancer drugs fail

While drug companies have been targeting insulin-like growth factor-1 receptor since it was first implicated in cancer almost two decades ago, the strategy has yet to bear fruit because of tumor resistance and off-target effects. AstraZeneca plc's MedImmune LLC subsidiary thinks it can avoid those issues by targeting the receptor's ligands IGF-1 and IGF-2 with its MEDI-573 antibody.

Jerry McMahon, SVP of R&D and head of the oncology innovative medicines unit at MedImmune, said preclinical data thus far support the mAb's mechanistic rationale, and Phase I data show no safety signals. The company plans to start Phase II trials in various solid tumors next half.

Insulin-like growth factor-1 (IGF-1) and IGF-2 are small polypeptides involved in regulating cell proliferation, survival, differentiation and transformation.

At least 12 compounds have entered clinical development to block the IGF-1 receptor (IGF1R; CD221) for cancer. The first compound to reach...

Read the full 743 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >